Get the Stockscreener App
1.68
2.44%
0.04
After Hours:
1.69
0.01
+0.60%
Enlivex Therapeutics Ltd stock is traded at $1.68, with a volume of 106.77K.
It is up +2.44% in the last 24 hours and up +29.23% over the past month.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
See More
Previous Close:
$1.64
Open:
$1.62
24h Volume:
106.77K
Relative Volume:
1.42
Market Cap:
$36.82M
Revenue:
-
Net Income/Loss:
$-27.16M
P/E Ratio:
-1.1507
EPS:
-1.46
Net Cash Flow:
$-25.87M
1W Performance:
+13.51%
1M Performance:
+29.23%
6M Performance:
-55.67%
1Y Performance:
+6.33%
1-Day Range:
$1.62
$1.75
1-Week Range:
$1.40
$1.75
52-Week Range:
$1.15
$4.59
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Name
Enlivex Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Stock (ENLV) Latest News
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA By Investing.com - Investing.com South Africa
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA - Investing.com Australia
EF Hutton maintains price target on Enlivex after trial advancement By Investing.com - Investing.com Australia
Enlivex Advances Knee Osteoarthritis Treatment Trial - TipRanks
Enlivex Receives Authorization from the Danish Medicines - GlobeNewswire
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan
ENLVEnlivex Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Enlivex Progresses to Phase II for Knee Arthritis Treatment - TipRanks
Enlivex Announces Positive DSMB Recommendation to Initiate - GlobeNewswire
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan
India News | ⚡Kolkata-Based Company Ellenbarrie Industrial Gases Files IPO Papers - LatestLY
Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Canada
Enliven Therapeutics Announces Details Regarding the - GlobeNewswire
Ellenbarrie Industrial Gases Files For IPO To Raise Rs 400 Crore - NDTV Profit
Enmy & The Cure - RAMzine
ENLV’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - Simply Wall St
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy - MSN
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy - Yahoo Finance
Enlivex Announces 2024 Shareholder Meeting - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at HC Wainwright - Defense World
Enlivex stock poised for growth with key trial readouts by 2025, says H.C. Wainwright - Investing.com India
Enlivex Therapeutics Financials Indicate Net Loss - TipRanks
Enlivex Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - StockTitan
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
Enlivex shares rise on EF Hutton's Buy rating By Investing.com - Investing.com Australia
Enlivex shares rise on EF Hutton's Buy rating - Investing.com India
Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 1.9% - Defense World
Enlivex Advances Psoriatic Arthritis Treatment with Allocetra™ - TipRanks
Enlivex Receives Regulatory Authorization For The - GlobeNewswire
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis - StockTitan
Enlivex Therapeutics and Biotricity Interviews to Air on the Red - WICZ
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent - openPR
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV) - Barchart
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent - WICZ
Enlivex Therapeutics (NASDAQ:ENLV) Trading 0.6% Higher - Defense World
Enlivex Commences Key Trial for Thumb Osteoarthritis - TipRanks
Enlivex Announces the Dosing of the First Patient in a - GlobeNewswire
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating ... - Yahoo Finance
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis - Yahoo Finance
Enlivex Therapeutics Ltd expected to post a loss of 22 cents a shareEarnings Preview - XM
Enlivex Webinar to Discuss Breakthrough Immunotherapy - TipRanks
Join Enlivex Therapeutics' Chief Executive Officer for a - GlobeNewswire
Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 - Yahoo Finance
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 - Yahoo Finance
Where Do Analysts Think The Enlivex Therapeutics Ltd (NASDAQ: ENLV) Is Going – Stocks Register - Stocks Register
Enlivex Therapeutics Ltd [ENLV] Is Currently -7.19 below its 200 Period Moving Avg: What Does This Mean? – The ... - The DBT News
Enlivex Therapeutics Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):